|Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2|
X Deng, N Dzamko, A Prescott, P Davies, Q Liu, Q Yang, JD Lee, ...
Nature chemical biology 7 (4), 203-205, 2011
|14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization|
RJ Nichols, N Dzamko, NA Morrice, DG Campbell, M Deak, A Ordureau, ...
Biochemical Journal 430 (3), 393-404, 2010
|Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization|
N Dzamko, M Deak, F Hentati, AD Reith, AR Prescott, DR Alessi, ...
Biochemical Journal 430 (3), 405-413, 2010
|CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK|
MJ Watt, N Dzamko, WG Thomas, S Rose-John, M Ernst, D Carling, ...
Nature medicine 12 (5), 541-548, 2006
|Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease|
RJ Nichols, N Dzamko, JE Hutti, LC Cantley, M Deak, J Moran, ...
Biochemical Journal 424 (1), 47-60, 2009
|The IkappaB kinase family phosphorylates the Parkinson’s disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling|
N Dzamko, F Inesta-Vaquera, J Zhang, C Xie, H Cai, S Arthur, L Tan, ...
PloS one 7 (6), e39132, 2012
|Whole body deletion of AMP-activated protein kinase β2 reduces muscle AMPK activity and exercise capacity|
GR Steinberg, HM O'Neill, NL Dzamko, S Galic, T Naim, R Koopman, ...
Journal of Biological Chemistry 285 (48), 37198-37209, 2010
|AMPK β1 deletion reduces appetite, preventing obesity and hepatic insulin resistance|
N Dzamko, BJW van Denderen, AL Hevener, SB Jørgensen, J Honeyman, ...
Journal of Biological Chemistry 285 (1), 115-122, 2010
|Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin|
JM Ye, N Dzamko, ME Cleasby, BD Hegarty, SM Furler, GJ Cooney, ...
Diabetologia 47 (7), 1306-1313, 2004
|AMPK‐independent pathways regulate skeletal muscle fatty acid oxidation|
N Dzamko, JD Schertzer, JG Ryall, R Steel, SL Macaulay, S Wee, ...
The Journal of physiology 586 (23), 5819-5831, 2008
|Inflammation is genetically implicated in Parkinson’s disease|
N Dzamko, CL Geczy, GM Halliday
Neuroscience 302, 89-102, 2015
|AMPK‐dependent hormonal regulation of whole‐body energy metabolism|
NL Dzamko, GR Steinberg
Acta physiologica 196 (1), 115-127, 2009
|Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms|
ME Cleasby, N Dzamko, BD Hegarty, GJ Cooney, EW Kraegen, JM Ye
Diabetes 53 (12), 3258-3266, 2004
|Liver‐specific suppressor of cytokine signaling‐3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity 1|
N Sachithanandan, BC Fam, S Fynch, N Dzamko, MJ Watt, S Wormald, ...
Hepatology 52 (5), 1632-1642, 2010
|Contraction-induced skeletal muscle FAT/CD36 trafficking and FA uptake is AMPK independent|
J Jeppesen, PH Albers, AJ Rose, JB Birk, P Schjerling, N Dzamko, ...
Journal of lipid research 52 (4), 699-711, 2011
|Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology|
N Dzamko, A Gysbers, G Perera, A Bahar, A Shankar, J Gao, YH Fu, ...
Acta neuropathologica 133 (2), 303-319, 2017
|Rosiglitazone treatment enhances acute AMP-activated protein kinase–mediated muscle and adipose tissue glucose uptake in high-fat–fed rats|
JM Ye, N Dzamko, AJ Hoy, MA Iglesias, B Kemp, E Kraegen
Diabetes 55 (10), 2797-2804, 2006
|Parkinson’s disease-implicated kinases in the brain; insights into disease pathogenesis|
N Dzamko, J Zhou, Y Huang, GM Halliday
Frontiers in molecular neuroscience 7, 57, 2014
|Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver|
JM Ye, G Frangioudakis, MA Iglesias, SM Furler, B Ellis, N Dzamko, ...
Endocrinology 143 (12), 4527-4535, 2002
|LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives|
F Atashrazm, N Dzamko
Clinical pharmacology: advances and applications 8, 177, 2016